04/09/2026
π¨π³ Major Breakthrough! New Hope for Vitiligo Treatment π
July 2026 brings exciting news from China's biopharma industry: InnoCare Pharma's oral TYK2 inhibitor, Soficitinib, has met its primary endpoint in a Phase II clinical trial for non-segmental vitiligo.
Results showed a 41.2% reduction in facial Vitiligo Area Scoring Index (F-VASI) after 24 weeks β compared to just 2.2% in the placebo group. Science is opening new doors for patients.
At Huahai Vitiligo Hospital, we embrace innovation while staying rooted in TCM wisdom. No matter how medicine advances, restoring internal harmony remains the foundation of true healing.
π Learn more: WhatsApp +86 17660367767